Literature DB >> 17576984

Progressive drug licensing: an opportunity to achieve transparency and accountability?

James M Wright1.   

Abstract

Mesh:

Substances:

Year:  2007        PMID: 17576984      PMCID: PMC1891125          DOI: 10.1503/cmaj.070685

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  2 in total

1.  Health Canada's Progressive Licensing Framework.

Authors:  Neil Yeates; David K Lee; Maurica Maher
Journal:  CMAJ       Date:  2007-06-19       Impact factor: 8.262

2.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.

Authors:  Patricia M Kearney; Colin Baigent; Jon Godwin; Heather Halls; Jonathan R Emberson; Carlo Patrono
Journal:  BMJ       Date:  2006-06-03
  2 in total
  4 in total

1.  Progressive licensing needs progressive open debate.

Authors:  Paul C Hébert; Matthew Stanbrook; Barbara Sibbald; Ken Flegel; Noni MacDonald; Amir Attaran
Journal:  CMAJ       Date:  2007-06-19       Impact factor: 8.262

Review 2.  Moving from opacity to transparency in pharmaceutical policy.

Authors:  Irfan Dhalla; Andreas Laupacis
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

3.  Will Open Government make Canada's health agencies more transparent?

Authors:  Paul C Hébert; Jane Coutts; Matthew B Stanbrook; Noni MacDonald; Ken Flegel
Journal:  CMAJ       Date:  2011-03-21       Impact factor: 8.262

4.  Can Health Canada protect Canadians from unsafe drugs?

Authors:  Paul C Hébert; Matthew B Stanbrook; Noni MacDonald; Ken Flegel; Jane Coutts; Stuart MacLeod
Journal:  CMAJ       Date:  2011-04-18       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.